

**Interindividual variability of carboxymethylenebutenolidase homolog, a novel olmesartan medoxomil hydrolase, in human liver and intestine**

Tomoko Ishizuka, Veronika Rozehnal, Thomas Fischer, Ayako Kato, Seiko Endo,

Yasushi Yoshigae, Atsushi Kurihara, and Takashi Izumi

Drug Metabolism and Disposition

Supplemental Table S1 The records of liver sample donors

No.	Sex	Age	BMI	Diagnosis
1	male	60	29	-
2	male	72	23	colon cancer
3	male	57	27	rectum carcinoma, liver metastasis segm V+VII
4	male	48	25	-
5	female	70	20	-
6	male	64	22	sigma carcinoma
7	female	57	24	sigma carcinoma
8	female	64	28	sigma carcinoma
9	male	77	26	chronic cholestasis
10	male	74	22	rectum carcinoma
11	female	62	24	gastrointestinal struma tumors
12	male	53	25	colorectal carcinoma, liver metastasis
13	female	68	28	adenocarcinoma, liver and lung failure
14	female	37	37	liver adenoma
15	male	72	31	hepatocellular carcinoma
16	female	47	19	colon carcinoma
17	male	73	29	-
18	female	41	20	sigma carcinoma, liver metastasis
19	male	54	23	neuroendocrine carcinoma
20	male	16	22	hepatocellular carcinoma
21	male	49	25	hepatocellular carcinoma
22	female	71	32	cholangiocellular carcinoma
23	male	95	unknown	rectum carcinoma, liver failure
24	female	61	26	sigma carcinoma, liver failure
25	male	68	30	sigma carcinoma, liver failure
26	male	73	28	rectum carcinoma
27	male	72	24	cholangiocellular carcinoma, lung metastasis
28	male	31	25	hemangioma
29	male	72	25	colon carcinoma
30	male	81	21	colon carcinoma, liver metastasis segm V
31	male	31	23	hepatic atrophy
32	female	69	33	cholangiocellular carcinoma
33	male	74	25	hepatocellular carcinoma segm II
34	female	62	31	rectum carcinoma, liver failure segm II+III
35	male	36	21	liver metastasis segm VIII
36	male	59	30	sigma carcinoma
37	male	69	26	liver metastasis segm VI
38	female	50	29	-
39	female	62	19	cholangiocellular carcinoma
40	male	66	43	colorectal liver failure